Molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors by Laine, Élodie et al.
  Universidade de São Paulo
 
2012-08
 
Molecular motions as a drug target:
mechanistic simulations of anthrax toxin
edema factor function led to the discovery of
novel allosteric inhibitors
 
 
Toxins,Basel : M D P I AG,v. 4, n. 8, p. 580-604, Aug. 2012
http://www.producao.usp.br/handle/BDPI/49708
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciência Interdisciplinar - IFSC/FCI Artigos e Materiais de Revistas Científicas - IFSC/FCI
Toxins 2012, 4, 580-604; doi:10.3390/toxins4080580 
 
toxins
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Review 
Molecular Motions as a Drug Target: Mechanistic Simulations 
of Anthrax Toxin Edema Factor Function Led to the Discovery 
of Novel Allosteric Inhibitors  
Élodie Laine 1, Leandro Martínez 2, Daniel Ladant 3, Thérèse Malliavin 4 and Arnaud Blondel 4,*  
1 Laboratoire de Biologie et de Pharmacologie Appliquée, Ecole Normale Supérieure de Cachan, 61, 
avenue du Président Wilson, 94235 Cachan cedex, France; E-Mail: elodie.laine@lbpa.ens-cachan.fr  
2 The Molecular Biotechnology Group, Institute of Physics of São Carlos, University of São Paulo, 
Av. Trabalhador Sãocarlense, 400, 13566-590 São Carlos, SP, Brazil; E-Mail: leandro@ifsc.usp.br 
3 Unité de Biochimie des Interactions Macromoléculaires and CNRS UMR 3528,  
Département de Biologie Structurale et Chimie, Institut Pasteur, 28, rue du Dr. Roux,  
75724 Paris Cedex 15, France; E-Mail: ladant@pasteur.fr 
4 Unité de Bioinformatique Structurale and CNRS UMR 3528, Département de Biologie Structurale 
et Chimie, Institut Pasteur, 25, rue du Dr. Roux, 75724 Paris Cedex 15, France;  
E-Mail: terez@pasteur.fr  
* Author to whom correspondence should be addressed; E-Mail: ablondel@pasteur.fr;  
Tel.: +33-1-4061-3693; Fax: +33-1-4568-8719.  
Received: 19 June 2012; in revised form: 4 July 2012 / Accepted: 18 July 2012 /  
Published: 31 July 2012 
 
Abstract: Edema Factor (EF) is a component of Bacillus anthracis toxin essential for 
virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous 
eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, 
nucleotides and/or ions, have been extensively characterized by X-ray crystallography. 
Those structural data allowed molecular simulations analysis of various aspects of EF 
action mechanism, including the delineation of EF and CaM domains through their 
association energetics, the impact of calcium binding on CaM, and the role of catalytic site 
ions. Furthermore, a transition path connecting the free inactive form to the CaM-complexed 
active form of EF was built to model the activation mechanism in an attempt to define an 
inhibition strategy. The cavities at the surface of EF were determined for each path 
intermediate to identify potential sites where the binding of a ligand could block activation. 
A non-catalytic cavity (allosteric) was found to shrink rapidly at early stages of the path 
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and was chosen to perform virtual screening. Amongst 18 compounds selected in silico and 
tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF 
allosteric inhibitors with IC50 as low as 2 micromolars. 
Keywords: anthrax; Edema factor; molecular modeling; virtual screening; allostery; 
transition path 
 
1. Introduction: Edema Factor, a Target of Choice to Fight Anthrax? 
1.1. Virulence Factors 
The virulence of Bacillus anthracis is mediated by the cooperative and synergistic action of three 
main proteins: a cell-binding protein, the protective antigen (PA), and two enzyme components, the 
lethal factor (LF) and the edema factor (EF). PA promotes EF and LF translocation in the cytosol of 
infected cells, particularly macrophages, where the two enzymes perform their damage-inducing 
processes, allowing bacteria to evade the immune system [1]. LF is a zinc-mediated metalloprotease, 
which cleaves MAP kinases and possibly other substrates. This impairs cell signaling, and results in 
the induction of apoptosis. 
EF, the main focus of the present study, is an adenylyl cyclase. It is activated within the eukaryotic 
target cells upon association with the host ubiquitous calcium sensing protein, calmodulin (CaM). The 
formation of the complex induces a large conformational change for EF. The activated toxin greatly 
increases the level of cAMP in the cells, and thus disturbs major intracellular signaling pathways 
ultimately leading to severe cellular dysfunction. More recently, EF has been shown to display other 
nucleotidyl activities, which could also contribute to toxic effects [2]. EF has been described to play 
central roles in the immune response impairment [3], during the infection [4] or the associated septic 
choc [5,6]. 
1.2. Bioterrorism Threat 
The ability of the bacterium to form very resistant endospores that can survive for decades in the 
soil and spread easily though water and air makes it a potential biological weapon [7,8]. In addition, 
the spores are relatively easy to produce, so that anthrax constitutes a microorganism of choice for 
bioterrorism. Consequently, it appears important to investigate ways to rapidly block anthrax infection 
and toxic detrimental effects, while at the same time ensuring and improving administration 
convenience and patient compliance [9,10]. 
1.3. Prevention and Treatments 
Several classical therapeutic approaches can be used to fight anthrax disease [11]. Since the original 
vaccine trials by Louis Pasteur in 1881, an attenuated Stern strain is still successfully used as a live 
avirulent vaccine in livestock [12]. Numerous human vaccines based on PA have been developed in 
the 1960s. However, due to intensive dosing regiment and high reactogenicity, these vaccines are 
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reserved for high-risk population treatment only [13]. Recently, anthrax capsules or whole inactivated 
spores have been incorporated in newly developed vaccines [14,15]. Efforts have also been made to 
combine smallpox and anthrax vaccines [16]. 
Antibiotics (penicillin, doxycycline and ciprofloxacine) [17] lead to rapid recovery if administered 
very early in the disease development. Although the number of naturally antibiotic-resistant strains  
is low [18], the emergence of resistance due to treatment exposure or in vitro engineering is a clear  
concern [19–21]. The latter observation and the existence of the non-natural bioterrorism threat call for 
more efficient and rapid ways to block anthrax infection and toxicity. 
1.4. Targets 
In that context, the anthrax toxins, which bear key virulence activities, can be regarded as privileged 
drug targets to fight the disease by means of selective inhibitors. Most of the drug design efforts have 
been focused on PA and LF so far. However, recent experimental evidences showing the crucial roles 
of EF in the repression of the immune response [3], in the infection [4], and in the septic shock [5], 
suggest that EF should be a valuable target for the design of small molecule inhibitors. 
1.5. Structural Data 
During the last ten years, to support fight against anthrax, a large effort in structural biology has 
been undertaken to better understand the biophysics of anthrax toxins translocation across cell 
membranes, activation in the cytoplasm and enzymatic activity. In particular, Edema Factor (EF) has 
been the subject of intensive investigation using X-ray crystallography (Table 1) in the laboratory of 
Wei-Jen Tang (Ben May Department for Cancer Research, University of Chicago). Once the 
appropriate crystallographic conditions had been determined [22], the first structures of EF isolated 
(1K8T) or in complex with CaM (1K90, 1K93) were solved at 2.90–2.95 Å resolution and  
published [23] in 2002. These structures pictured an unexpected mode of action for calmodulin (CaM). 
CaM and EF form a tight complex in which CaM adopts an extended form, while EF conformation 
strongly differs from its CaM-free form (about 9.5 Å RMS difference, Figure 1). NMR  
measurements [24] clarified the influence of calcium on the formation and stability of the complex.  
In 2005, Shen et al. published additional EF-CaM complex structures at 3.0 Å resolution. It included 
the N-terminal PA binding domain of EF as well as 2, 3, or 4 bound calcium ions (1XFX, 1XFY, or 
1XFV respectively). However, these structures collected in different conditions did not reveal any 
major variation, and thus, crystallographic studies could not explain the influence of calcium on the 
complex stability. 
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Table 1. List of PDB structures containing the Edema Factor. 
PDB id Reference Description 
1K8T [23] EF in free inactive form 
1K90 [23] EF in complex with CaM and 3'-deoxy-ATP 
1K93 [23] EF in complex with CaM 
1LVC [25] EF in complex with CaM and 2'deoxy 3' anthraniloyl ATP 
1PK0 [26] EF in complex with CaM and PMEApp a 
1S26 [27] EF in complex with CaM and 5' met-ATP 
1SK6 [28] EF in complex with CaM and cAMP, PPi b 
1XFU [29] EFΔ64 c in complex with CaM 
1XFV [29] EF in complex with CaM and 3'-deoxy-ATP 
1XFW [29] EF in complex with CaM and cAMP 
1XFX [29] EF in complex with CaM, 10 mM calcium 
1XFY [29] EF in complex with CaM 
1Y0V [29] EF in complex with CaM and PPi 
a Adefovir diphosphate; b pyrophosphate; c an Edema Factor (EF) truncation mutant where the sequence  
33–63 was removed. 
Figure 1. X-ray crystallographic structure of the EF-CaM complex [23]. (A) EF and CaM 
are displayed in cartoon representations. Calmodulin (CaM) is in green lime and loaded 
with two calcium ions (spheres in orange). The helical domain Hel of EF is in wheat, the 
CA and CB domains that form the catalytic core of EF are in marine and purple 
respectively. The three switches SA, SB and SC are colored in cyan, magenta and red. The 
catalytic residues and the ligand 3'-deoxy ATP are drawn in sticks and the Yb3+ ion is 
drawn as a magenta sphere; (B) Cartoon and surface representations of CaM structure are 
displayed from different views. On the left, the eight helices of CaM are labeled: A, B, and 
C in N-CaM; D and E in the interlinker; and F, G, and H in C-CaM. Calcium-binding loops 
S1 and S2 in N-CaM, S3 and S4 in C-CaM are indicated. Two Ca2+ ions are bound to S3 
and S4 (spheres in orange). On the right, CaM hydrophobic patches as defined by  
Yang et al. [30] are colored in yellow and the other hydrophobic residues are colored in 
forest green. 
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1.6. EF Inhibitors 
In the past decade, intensive efforts have been devoted to the design of small molecules able to 
inhibit EF and that could be used as tools to study anthrax toxin effects on cells and could also be 
potential leads toward anthrax therapeutics. Recent works have highlighted the importance of EF in 
host-pathogen interactions and have further validated the idea that EF may effectively be a valuable 
therapeutic target to fight against the development of anthrax [4]. 
In principle, three major modes of action can be conceived for small molecules acting as inhibitors 
of EF, each targeting a distinct step along the EF intoxication process, namely (i) EF entry into target 
cells; (ii) EF activation by CaM and finally; (iii) EF enzymatic activity. We will not further describe 
here the first mode, as the corresponding molecules are mainly directed toward the PA component 
which is responsible for the internalization of EF (and LF) into eukaryotic cells (see [31]). Most of the 
known EF inhibitors target the active site (Figure 2A–D) and only two inhibit the EF/CaM interaction 
(Figure 2E), as summarized below. 
Figure 2. Examples of potent inhibitors of EF toxin component. Inhibitors in panel A to D 
were identified by targeting EF active site. (A) ethyl 5-aminopyrazolo[1,5-a]quinazoline- 
3-carboxylate, [32]; (B) (9-[2-[[bis[(pivaloyloxy)methoxy]phosphinyl]methoxy]ethyl] 
adenine; or bis-POM-PMEA, [26]; (C) 3-[(9-oxo-9H-fluorene-1-carbonyl)-amino]-benzoic 
acid, [33,34]; (D) MANT-CTP and propyl-ANT-ATP, [35]; (E) 4-[4-(4-dichloro-phenyl)-
thiazolylamino]-benzenesulfonamide (10506-2A) was first identified in a cell based assays 
and then selected for its ability to block EF–CaM binding. 4-[[4-(4-nitrophenyl)-2-
thiazolyl] amino]-benzenesulfonamide (nitro10506-2A) was identify as a non-toxic 
derivative of the former [36]. They appeared to bind the helical domain of EF, thus being 
allosteric as the compounds of the TUA family, which will be described below (Figure 5, and 
ref. [37]). 
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1.6.1. Inhibitors Targeting EF Active Site 
Following the description of EF/CaM structures, the first discovery of EF inhibitors using  
structure-based approach was reported in 2003 by the team of W.-J. Tang [32]. They were directed 
towards the catalytic site of EF and the identification of ATP competitors. About 200,000 molecules 
(from the Available Chemical Directory) were docked in multiple orientations and conformations into 
the ATP binding site (Protein Data Bank code 1K90). About twenty molecules with high scores were 
selected for further experimental characterization. Among them, few were shown to specifically inhibit 
EF in vitro and to block the cytotoxicity of EF (+PA) toward eukaryotic cells. These authors thus 
identified a family of quinazoline compounds which selectively inhibited EF, with Ki values of  
20–50 µM for the best one (ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate, Figure 2A), 
without inhibiting mammalian adenylyl cyclases (MAC(s)). Interestingly, these molecules also 
inhibited the related CaM-dependent adenylate cyclase toxin, CyaA, produced by Bordetella pertussis 
the causative agent of whooping cough. 
The same team later examined a series of nucleotide analogues that had been previously clinically 
approved for a variety of viral infections (and would thus exhibit favorable pharmacological 
properties). They found that adefovir dipivoxil (9-[2-[[bis[(pivaloyloxy)methoxy]phosphinyl]methoxy] 
ethyl]adenine; or bis-POM-PMEA, Figure 2B), a drug clinically approved to treat chronic infection of 
hepatitis B virus, can efficiently block the EF induced cAMP accumulation in mammalian cells and the 
resulting pathological effects such as alteration of cytokine production in macrophages [26].  
This drug is converted inside the cells by cellular kinases into a diphosphate derivative, PMEApp, a  
non-cyclizable ATP analogue that binds with high affinity of the catalytic site of EF as revealed by  
X-ray crystallography. Kinetic analysis revealed that PMEApp is a highly potent competitive inhibitor 
(Ki = 27 nM) of EF. Since this original report, adefovir dipivoxil has been used to explore the role of 
EF in anthrax pathogenesis [3,4,38]. 
To identify non-nucleotide inhibitors of EF, Chen et al. [33] used a structure-based method in 
which a 3D-pharmacophore, fitting the EF active site, was constructed from fragments. A small set of 
compounds exhibiting the best docking scores in virtual screening were tested in a cell-based assay for 
their ability to reduce cAMP release by cells treated with EF/PA. Four compounds having different 
molecular structures exhibited IC50 values in the low micromolar range in these assays [33]. More 
recently, the same team used molecular docking to predict improvements in potency and solubility of 
one of these molecules (3-[(9-oxo-9H-fluorene-1-carbonyl)-amino]-benzoic acid, Figure 2C). A 
structure-activity relationship (SAR) analysis of a number of variants yielded few derivatives with 
superior pharmacological properties as compared to the initial lead compound [34]. 
The group of R. Seifert also developed potent and selective inhibitors of EF (as well as of 
Bordetella pertussis CyaA) based on various purine and pyrimidine nucleotides modified with  
N-methylanthraniloyl (MANT)- or anthraniloyl (ANT) groups at the 2'(3')-O-ribosyl position.  
MANT-CTP and propyl-ANT-ATP were the most potent EF derivatives characterized (Figure 2D, [35]). 
In in vitro assays, these compounds inhibited EF competitively with Ki of 100 nM and 80 nM, 
respectively and with a good selectivity relative to MACs, although it is obviously difficult to obtain 
highly specific competitive inhibitors of an ATP-utilizing enzyme. Interestingly these results showed 
that EF would have a preference for the cytosine base unlike other adenylyl cyclases, which would 
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allow better selectivity and potency [35,39]. No in vivo studies have been reported yet with these 
nucleotides analogs that might require further engineering to be rendered cell permeable. 
1.6.2. Inhibitors Targeting the EF-CaM Interaction 
As EF is essentially inactive in the absence of CaM, preventing its interaction with its activator 
represents an efficient and potentially more selective approach to inhibit this enzyme. Yet, designing 
small molecule able to efficiently inhibit protein-protein interaction still remains a challenging task, 
and there are to date only two examples of inhibitors that act by preventing CaM binding and therefore 
EF activation. The first inhibitor of that class was identified by Tang’s group by screening a library 
with a combination of cell-based assay and a protein binding-based screen [36]. They first identified 
compounds that could block the EF-induced toxicity in a cell-based assay from a library of about 
10,000 molecules. Selected molecules were further evaluated by testing their ability to prevent  
EF binding onto immobilized CaM with surface plasmon resonance (SPR). Among the 24 tested 
compounds, one, a 4-[4-(4-dichloro-phenyl)-thiazolylamino]-benzenesulfonamide, could bind to EF 
and prevent its activation by CaM. This compound, 10506-2A (Figure 2E), inhibited EF–CaM binding 
with an IC50 of 15 μM. A combination of fluorescence spectroscopy and photolabeling studies showed 
that the molecule targets the Helical domain of EF (C-terminal, Figure 1), which is involved in the 
binding of CaM. The 10506-2A inhibitor was selective for the EF-CaM interaction as it had no effect 
on two tested CaM-regulated MACs: calcineurin, a Ser/Thr phosphatase, and adenylyl cyclase 1 
(mAC1). Yet, 10506-2A could also inhibit B. pertussis CyaA even though this toxin has a  
CaM-interacting region that is quite distinct from that of EF. As compound 10506-2A showed 
significant toxicity towards eukaryotic cells at 30–50 μM concentrations, Lee et al. [36] further 
characterized a series of 10506-2A analogs. They found one derivative, 4-[[4-(4-nitrophenyl)-2-
thiazolyl] amino]-benzenesulfonamide (nitro10506-2A, Figure 2E) that was non-toxic to eukaryotic 
cell lines while it still blocked CaM binding to EF and prevented EF activation. The second family of 
inhibitors that prevent CaM-EF interaction [37] was designed through an in silico structure-based 
approach and will be described in details in the following sections. 
1.7. Objectives 
The purpose of the present manuscript is to show how computational analysis of the molecular 
mechanisms of EF activation by CaM led to a rational strategy to identify new inhibitors of the toxin. 
For that purpose, advanced computational biophysics techniques were applied to conceive and 
elaborate the novel design approach. The first ground for this strategy was established using calcium 
influence as a probe to understand the internal dynamics, energetics and thermodynamic stability of 
EF/CaM interaction. Then, the catalytic mechanism and the role of divalent ions were thoroughly 
investigated. Finally, a drug discovery strategy could be established by extensive exploration of 
conformational transition involved in EF activation and analysis of the associated cavity evolution. An 
allosteric site controlling CaM association and the concomitant EF activation could be identified. It 
was used to select small molecules by virtual screening for their suitability to bind to this site and 
block the CaM-induced EF activation. Several molecules selected in silico were characterized 
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experimentally and a series of thiophen ureidoacid derivatives (TUA) were shown to inhibit EF 
activity. This validated the proposed allosteric site as a target for drug design. 
2. Interplay between EF, Calmodulin and Calcium Ions 
2.1. Structure of EF-CaM Complex 
EF is composed of an N-terminal PA-binding domain (residues 1 to 291), a catalytic core domain 
(residues 292 to 622), and a C-terminal helical domain (Hel; residues 660 to 767). In the EF-CaM 
complex, CaM is inserted between the catalytic core and the helical domain of EF (Figure 1A). The 
catalytic core of EF is subdivided in two sub-domains: CA (residues 292–349 and 490–622, in marine) 
and CB (residues 350–489, in purple). Three loops, called Switches A, B, and C, or SA, SB and SC 
reorganize and assemble upon CaM binding to form and stabilize the active conformation of the 
catalytic site at the CA–CB interface (catalytic residues in licorice). The switch A region (domain CA, 
residues 502–551, in cyan) is in direct contact with the C-terminal lobe of CaM in the complex. Switch 
B (domain CA, residues 578–591, in magenta) adopts an active conformation forming a wall of the 
active site. Switch C (residues 630–659, in red) embraces CaM and maintains Switch B in place. 
Switch C also connects the catalytic core to the helical domain, Hel (in wheat color). The Hel domain 
is formed by four helices and directly interacts with the N-terminal lobe of CaM. 
CaM is a small and very flexible protein bearing four calcium binding sites (Figure 1B). Each 
binding site is formed by a helix–loop–helix motif called “EF-hand”. The four binding sites are 
organized in pairs in two globular lobes, N-CaM and C-CaM, which are connected by a flexible  
inter-linker. Alpha-helices A, B, C, and D form the N-CaM domain, while helices E, F, G, and H form 
C-CaM. A fraction of helices D and E flanking their junction form an inter-linker region. The  
calcium-binding loops are located between helices A and B for site S1, helices C and D for site S2, 
helices E and F for site S3, and helices G and H for site S4. 
The influence of calcium binding on CaM conformation and properties has been largely 
documented [40–44]. The α-helices forming CaM “EF-hand” motifs open upon calcium binding. This 
opening exposes hydrophobic patches [30], which can then promote interactions with amphipatic 
helical peptidic segments that commonly constitute the CaM-interacting sites of most CaM target 
enzymes. In the EF-CaM complex, C-CaM adopts an open conformation with exposed hydrophobic 
patches, whereas N-CaM adopts a closed conformation (Figure 1B). 
2.2. Calcium Probes the Modulation of EF Activity by CaM 
Calcium concentration has also a strong effect on EF-CaM complex, which could, to a certain 
extent, be considered as a ternary complex, involving EF, CaM and calcium ions. The affinity of EF 
for CaM has been shown to depend on calcium binding [24]. The complex appeared most stable with  
2 Ca2+ bound in titration assays. The complex with 4 Ca2+ was marginally formed, and no EF-CaM 
complex could be observed in the absence of calcium. Calcium ions first bind with high affinity to 
sites S3 and S4 of the C-terminal CaM lobe (C-CaM). Then, in the N-terminal CaM lobe (N-CaM), 
sites S1 and S2 are progressively populated with increasing concentration of calcium ions. The 
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modulation of the EF/CaM interaction by calcium provides a useful probe to further analyze the 
biophysical ground of EF-CaM complex formation and stability. 
The interactions at play in the EF-CaM complex were characterized by molecular dynamics (MD) 
simulations performed with different numbers of bound Ca2+ ions. Following the experimental 
observations of [24], the number of calcium ions was modified in silico by removing or, on the 
contrary, adding two calcium ions to the 2 Ca2+-loaded complex to model the calcium-induced changes 
in EF and CaM conformations. The bending of CaM central linker observed with 0 and 4 Ca2+ ions 
suggested [45] that CaM acts as a spring. Its stiffness and opening would be tuned by calcium binding 
to optimally place EF Hel and CA domains and fold Switches A, B and C in their catalytically 
competent conformations. 
2.3. Calcium Signal Propagation throughout EF-CaM Residue Network 
As stated in the introduction, despite the important role of calcium, crystallographic structures of 
the EF-CaM complex with different packing geometries and different numbers of bound calcium  
ions do not display major variations [29]. Nonetheless, the Hel domain adopts slightly different 
conformations at the interface with CaM in the two sets of EF-CaM structures (Drum et al. 2002 [23] 
and Shen et al. 2005 [29]). These slight structural variations reflect subtle energetic equilibria and 
transfers arising from conformational and local flexibility modulation [46–48]. 
The propagation of the calcium signal through the residue network of EF-CaM was modeled using 
several recently developed approaches [49]: the generalized correlation [50], the local feature  
analysis [51], and the energy dependency maps [52]. The dynamical and energetical contributions at 
play within the complex were analyzed in details and compared in the different calcium level 
conditions. This analysis showed that the arrangement of the domains of the two partners in the 
complex can be visualized as a “house-of-cards” assembly of dependent sub-domains. In that 
assembly, CA, CB end Hel domains of EF act as foundation cards and the other structural elements,  
N-CaM, C-CaM, SA and SC, assemble on top with ranks in interaction strength that are shuffled by 
calcium removal or addition (Figure 3A,B). The most stable complex, with two bound calcium ions, 
corresponded to balanced interactions and influences between the domains of the complex. This 
molecular modeling investigation can be paralleled with the transmission of conformational  
signal [48,53,54] in elastic network models [46,47,55]. 
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Figure 3. Calcium effect on the EF-CaM complex. Energetical influences and dynamical 
correlations computed in the EF-CaM complex. (A) the energetical influences between the 
different domains of EF (in blue) and CaM (in green) are drawn as arrows whose color  
and thickness indicate the intensities of the influences, as seen by MMPBSA energy 
dependency maps [49]; (B) the residues of the EF-CaM complex are represented by their 
C-α atoms and colored in cyan when their dynamical correlations are low (<0.5), in green 
when their correlations are mean (0.5–0.6) and in magenta when their correlations are high 
(>0.6). In the 2 Ca2+ bound complex (in the middle), the energetical influences are located 
in the vicinity of the EF/CaM interface and the most residue are correlated. Removal of 
calcium (on the left) reduces the energetical influences and a region of uncorrelated 
residues appears at the interface between the two proteins. Upon calcium addition (on the 
right), new energetical influences are observed even at long distances, and three sets of 
highly correlated residues were observed; (C) Interface between the Hel domain of EF and 
N-CaM in the EF-CaM complex. The conformations taken after 8 ns of MD simulations 
starting from 1K93 (on the left, chains C and F) and 1XFX (on the right, chains A and O) 
are represented in cartoon. EF Hel domain is colored in wheat with the inter L–M loop 
highlighted in yellow. N-CaM is colored in green lime. Residues involved in the EF/CaM 
interaction and residues forming CaM calcium binding sites S1 and S2 are drawn in sticks. 
Calcium ions are displayed as orange spheres. The inserts represent the electron density 
maps of the starting crystallographic structures, contoured at 1.10 s; (D) Principles of 
locally enhanced sampling (LES) methods; a snapshot from the LES simulations (protein 
in cartoons, ions in green spheres): to enhance the probability of calcium dissociation 
events, one Ca2+ ion is replicated in multiple copies; (E) Principles of free energy 
perturbation (FEP). The thermodynamic cycle used in the FEP method to compare calcium 
dissociation free energies between two protein conformational states (1k93-4Ca and  
1xfx-4Ca complexes). 
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Figure 3. Cont. 
 
2.4. Interplay between EF/CaM and Ca/CaM 
Energy dependency maps showed that the interface between EF and CaM is central to the 
architecture of the complex. This interface was explored in more details by recording two molecular 
dynamics trajectories starting from two different crystallographic structures of EF-CaM that represented 
two micro-states [56]. One trajectory was started from the 2Ca2+-loaded EF-CaM crystallographic 
structure (1K93 [23]) in which two additional calcium ions were added. The other trajectory was 
started from a crystallographic structure already containing four calcium ions (1XFX [29]). 
The electronic densities observed in 1K93 and 1XFX displayed different flexibility and backbone 
conformations of the inter L-M loop of the Hel domain of EF, at the interface with N-CaM  
(Figure 3B,C). Based on this observation, it was supposed that the lower affinity of the N-CaM 
calcium binding sites S1 and S2 in the complex could be explained by conformational constraints 
induced by the Hel domain. This hypothesis was confirmed by molecular dynamics analyses [56], 
which highlighted the interplay between the constraint exerted by the Hel domain and the affinity of 
the calcium sites. Indeed, when the first “EF-hand” of CaM was more firmly attached to EF 
(simulation starting from 1XFX), the coordination of the Ca2+ ions was looser in the calcium binding 
loops of sites S1 and S2 than in the other simulation (starting from 1K93) (Figure 3C). The affinities of 
these sites for the calcium were also evaluated [56] with Local Enhanced Sampling (LES, or multiple 
copies) simulation and with FEP/MD simulations (Figure 3C) and were found to correlate with the 
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Ca2+ ions coordination quality (number of interactions and their recorded distances along  
the trajectories). 
Computational biophysics analysis of EF/CaM/Ca2+ interactions has revealed that the interface 
between the Hel and CA domains is the most sensitive part of the EF-CaM complex to the binding or 
removal of calcium on CaM. This direct influence of the number of bound calcium ions on EF 
activation [25] suggests that this sensitive region, which notably involves SA and SC, should be a 
favorable target locus for allosteric EF inhibitors candidates. 
3. Catalytic Properties 
EF is an adenylyl cyclase turning ATP into cyclic-AMP (cAMP) more efficiently than MACs, as 
displayed in Figure 4A. It was also reported recently to have cytidylyl cyclase (CC) and uridylyl 
cyclase (UC) activities [2]. The canonical mechanism of these cyclizations involves the nucleophilic 
attack of ribose hydroxyl in position 3' to the Phosphorous of the α-phosphate group. This attack can 
be catalyzed by, first, the abstraction of the proton attached to hydroxyl in position 3' and, second, the 
stabilization of the highly charged pyrophosphate (PPi) group in formation [57,58]. Adenylyl cyclases 
accelerate the reaction by both mechanisms. The proton is believed to be removed by some proximal 
Lewis base, which are suggested, for example, to be aspartate or asparagine residues in MACs [58,59]. 
Stabilization of the leaving PPi group is achieved by binding to metal ions and cationic residues 
(lysines and arginines) [60]. Crystallographic structures have provided detailed pictures of the 
molecular arrangement of these constituents. This is especially the case for the active site and the 
number and position of metal ions in MACs. However, analysis of EF crystallographic structures 
raised unexpected questions on the catalytic site definition, which suggest that the details of the 
mechanism diverge from that of MACs. 
3.1. EF Catalytic Site Structures 
EF catalytic site is located between CA and CB domains, and the ATP binding pocket includes 
residues from six segments of the protein (Figure 1, [22]). 
EF crystallographic structures were determined with different molecules bound to the catalytic site, 
different substrate conformations and different cationic binding modes [23,25,28,29]. These structures 
brought information about two different states of the catalytic site: (i) the state before the enzymatic 
reaction, with the ATP substrate analog 3'-deoxy-ATP, for which two structures have been determined 
(1XFV, 1K90); and (ii) the state after the reaction with the products cAMP and PPi, for which one 
structure is available (1SK6). As these structures correspond to different functional states, the position 
of the ions should reflect different binding properties. Furthermore, as various ion-binding modes were 
isolated for each state, their roles in substrate binding, catalysis and product release remained to be 
clarified, especially considering that the reaction involves highly charged groups. Noteworthy, 1XFV 
is the only structure obtained with Mg2+ ions, but at a concentration, which inhibits the reaction [25]. A 
substrate analog, 3'-deoxy-ATP, which cannot undertake the reaction towards products, was used 
instead of ATP for the reactant form. Structure 1SK6 was obtained with the highly charged Yb3+ which 
might have allowed trapping of the products in the active site. Hence, the details of these structures 
may differ from the functional states of the protein. Figure 4B,D depict the arrangement the substrates, 
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ions and key residues in the active site, inferred from available crystallographic structures by 
substitution of ions and substrate with Mg2+ and/or ATP when necessary. 
Figure 4. ATP cyclization mechanism. The arrangement of the active site suggested by 
crystallographic structures with (A) the basic cyclization reaction; (B) substrate and one 
metal ion (based on PDB structure 1K90); (C) products and either one and two metal ions 
(based on PDB 1SK6); and (D) the substrate and two metal ions (based on PDB 1/XFV). 
For clarity, all ions are represented as Mg2+, the actual catalytic ion, and the substrate 
analogs are shown as restored to ATP. 
 
The first solved structure [23], corresponding to Figure 4B displays the substrate with only one 
metal ion in the active site. It was firmly attached both to the enzyme (through residues D491, D493 
and H577) and to ATP phosphate groups. This differed from the consensual binding of two Mg2+ ions 
found in MACs and suggested differences in the detailed catalytic mechanisms. Nevertheless, the 
substrate position in that structure is similar to that of MACs. 
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The arrangement of the products bound to EF in presence of Yb3+, raised additional questions about 
the catalytic mechanism (Figure 4C, [28]). The electronic density suggested possible binding of either 
one or two ions in the active site. The one-ion binding mode is similar to the substrate-bound model 
previously described, with coordination by D491, D493 and H577, and interaction with PPi and cAMP 
phosphate oxygens (MgA
2+ ion in Figure 4C). By contrast, the two-metal-ion binding mode suggests a 
weaker binding of the ions to the protein; one being mostly coordinated by D491 and PPi and the other 
mostly coordinated by H577 and cAMP. This arrangement resembles the two-metal-ion binding mode 
of MACs [60,61]. 
Finally, an experimental structure of the EF-ligand complex with two Mg2+ ions, the actual catalytic 
ions, was solved [29]. This suggests that EF could adopt the consensual MAC active site arrangement. 
However, as will be discussed below, the position of the ions in that structure (Figure 4D) seems rather 
resulting from a crystallographic artifact than a functional arrangement. Indeed, MgA
2+ is coordinated 
by the protein in a single-ion mode like in Figure 4B, whereas the other ion, MgB
2+  is mostly 
coordinated by ATP and makes poor contacts with the protein (Figure 4D). 
3.2. Insights from Computational Modeling 
Some experimental evidences suggest that EF and MACs might operate with different mechanisms. 
First, EF has a cAMP production rate of 1–2000 s−1, much higher than that of MACs. Second, the 
Mg2+ concentrations used to solve the two-Mg2+ structure 1XFV inhibit the catalytic reaction [25]. 
Thus, its relevance to interpret the catalytic mechanism is questionable. Third, comparative analysis of 
MAC and EF structures with two ions shows different substrate conformations and ions positions [61]. 
Hence, despite the same number of ions in the active sites of MACs and EF, inferring a conservation 
of the mechanism would be an oversimplification. Last but not least, the structure with a substrate 
conformation resembling to that of MACs was obtained with a single ion (Figure 4A), and is the one 
that appears to be compatible with the structure of the bound products [61]. 
Extensive molecular dynamics simulations and modeling have been performed [61,62] to analyze 
the relevance of each binding mode with respect to association, dissociation and affinity of the 
substrate and products. 
Conventional Molecular Dynamics (MD) simulations of ATP and products bound to the active site 
were performed first [61]. These simulations suggested that: (1) The single ion in 1K90 (Figure 4B) is 
very effective in bridging the interaction of the phosphate tail of ATP to the active site residues, with 
strong interaction energies with both of them; (2) The ions in the two-ion binding mode (Figure 4D) 
are not as effective for ATP binding, because MgA
2+ ion is tightly attached to the protein, but loosely to 
ATP, while MgB
2+ is essentially only coordinated by the substrate. Accordingly, ATP displays a larger 
mobility and flexibility in the active site of this conformation in MD relative to the one-ion binding 
mode; (3) The presence of two-ions in the product-bound active site firmly attach PPi and cAMP 
(Figure 4C). The global effect of this strong binding is ambiguous, as it may accelerate the reaction by 
reducing the transition state energy, but it could also slow down the release of products and thus the 
reaction. These simulations support that structure 1XFV (substrate and two-ions) would not correspond 
to a functional state. 
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Substrate, products and ion association and dissociation have large activation barriers and occur in 
too long time-scales for conventional MD. Hence, to analyze the effect of their conformation on their 
associations and dissociations in details, non-conventional MD techniques were used [62]. Locally 
Enhanced Sampling (LES) probes possible dissociation routes for substrates and products, by 
increasing the number of sampled ligand conformations and by reducing their interactions with the 
protein. The LES dissociation routes were then studied in details with regular interaction potential by 
Steered Molecular Dynamics (SMD) simulations. 
ATP dissociates (and putatively associates) by diffusing in a wide opening between Switch C and  
α-Helix D, while the products, PPi and cAMP, dissociate from the less opened active site through 
solvent-accessible channels in opposite directions [62]. These general trends are independent of the 
detailed binding modes within the precision of LES simulations. In agreement with conventional MD 
results, products dissociation was significantly hindered by the presence of two ions in the binding  
site, due to very specific, close-contact ion-phosphate interactions. Therefore, presence of two ions 
appeared unfavorable for product dissociation. An interpretation of the ions electronic density 
spanning different positions in the product-bound structure (Figure 4C) could be that they correspond 
to three different ion-binding modes, favoring the attachment of the substrate (central position), the 
dissociation of cAMP, or that of PPi respectively [62]. 
Interestingly, simulations indicate that the second ion, which is only coordinated by ATP in 1XFV 
structure, systematically dissociates with ATP, without requiring breaking ion-protein interactions. 
Thus, 1XFV structure may reveal a transient state in which ATP would reach the active site with the 
second ion. Noticeably, the dissociation of ATP is easier from 1XFV structure than from that of 1K90 
where the single ion, tightly bound to the protein and ATP, provides rigidity (conventional MD [61], 
and Figure 4B). 
From the analysis of crystallographic models and simulations, a plausible model for EF function 
could be the following: (i) The association of Mg2+ bound ATP to a one-ion catalytic site, in a 
conformation resembling that of structure 1K90; (ii) The presence of two Mg2+ ions in the catalytic site 
would induce a 1XFV like conformation, which would reshuffle and lead to the expulsion of the B
2+Mg  
like ion, thus restoring a 1K90 like conformation competent for catalysis (Figure 4B,D). This 
reshuffling of Mg2+ ions in the active site may favor transient catalytic competent conformers of  
ATP [61]. Indeed, paradoxically, the 1K90 binding mode resembles to that found in MACs structure 
despite the presence of one ion only. Alternatively, Mg2+ free ATP molecules, present in low 
concentration could also enter the site, directly leading to the 1K90 like conformation. After (iii) 
cyclization; (iv) the dissociation of products could be facilitated by reshuffling of Mg2+ ions within 
their multiple possible positions and the entry of new Mg2+ ions to replace those that could have left 
with one of the products. This mechanism, based on a one-ion catalytic step with possible transient 
presence of two ions would be different from that of MACs. They suggest a rather plastic catalytic site 
allowing Mg2+ reshuffling. Obviously, further experiments and simulations are necessary to validate or 
refute this mechanism. 
Other questions concerning the catalytic mechanism remain. Is His351 pulling the 3' hydroxyl 
proton out as a Lewis base (Figure 4B–D)? Experimental evidences are not conclusive: this residue 
may be found at distances up to 7 Å from the hydroxyl groups of ATP (in 1XFV), thus not allowing the 
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formation of an hydrogen bond with hydroxyl in position 3' (Figure 4D, [29]). Experiments clearly show 
that His351 is fundamental for EF activity, but its role remains undetermined, as its substitution by 
other potential Lewis bases (as Asn) do not completely restore the enzymatic efficiency [63]. It has 
been proposed recently that Mn2+ could act as a physiological ion for ACs together with or in place of 
Mg2+ [64,65]. Mn2+ was found to occupy the two-ions binding sites of MACs with affinities different 
form that of Mg2+ [60]. The suggested roles of Mn2+ could challenge the current models of EF action 
mechanism. Hence, at this stage, many factors are still unknown, and it is difficult to identify the 
binding mode and substrate conformation actually involved in the reaction path and the transition state. 
The absence of a precise definition of the mechanism makes the analysis of the reaction difficult at 
electronic level since multiple hypotheses would have to be explored. 
4. Conformational Transition and Inhibitors Discovery 
4.1. Challenges in Rational Inhibitor Design 
The rational design of new biomolecular inhibitors faces several challenges: (1) Identify a protein 
and a specific pocket or cavity at its surface to exert an effective therapeutic effect; (2) Search for 
ligands that bind with sufficiently high affinity to such a cavity to implement actual inhibition in 
physiological conditions; (3) Discover diverse chemical scaffolds to overcome drug design adversity, 
due, for instance, to various sources of attrition in drug development or to the apparition of drug resistance. 
A straightforward approach to search for inhibitors is to target active sites or sites associated with a 
known effector. However, such a strategy is prone to identification of inhibitors resembling already 
known ones. For example, one known inhibitor of EF is the metabolite of adefovir, an ATP analogue, 
which binds the catalytic site with high affinity (see above, [26]). Although adefovir has been 
approved for the treatment of hepatitis B, it displays toxicity at high doses. Actually, the high degree of 
conservation of ATP-binding sites limits the selectivity of the inhibitors that target such sites and the 
high cellular concentration of ATP (around 5 mM, [66]) diminishes their efficacy. 
As a consequence, any drug design strategy targeting the active site of EF bears a significant risk of 
designing promiscuous ATP analogues that will provoke detrimental side effects. In addition, as shown 
in section “Catalytic properties”, available structures do not provide an unequivocal catalytic 
mechanism nor a simple ion-binding pattern. Theses mechanistic uncertainties suggest an even 
stronger risk associated with the targeting of EF catalytic site in a rational drug design approach. 
The question is then how can we identify another type of inhibitory site? Searching for possible 
inhibition mechanism, we can consider that it can operate either statically, by competition or by 
impeding the binding of functional partner, or, alternatively, dynamically, through allostery, which can 
also involve alteration of partner binding. The first class of static inhibition, especially competition, is 
rather classical, and it seems that exploiting the second dynamical category offers a larger number of 
opportunities. This second route appears promising, but requires a method to identify a novel-binding 
site at the surface of the protein, in which a small molecule could block the targeted activity upon 
binding. Noteworthy, use of a yet unexploited site would create ideal opportunities to design 
innovative molecules. Hence, targeting EF site different from the catalytic pocket appears as an 
attractive and valuable alternative, which is worth the attempt. 
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4.2. Design Strategy to Target EF Activation Mechanism 
Identification of a yet unexploited inhibitory site is a motivating challenge. Nonetheless, operating 
inhibition that exploits a dynamical mechanism requires technologies to determine relevant locations  
at the surface of the target protein. Identifying the most promising target sites requires a deep 
understanding of the function and activation/deactivation molecular mechanisms to identify the 
essential motions as well as the associated cavity evolution. Indeed, the target site should directly or 
indirectly be involved in the function, but it should also be sensitive and responsive enough to the 
binding of a small compound to exert an effect. 
The outline of the rational strategy used to identify new inhibitors of the EF toxin, and which could 
in principle be employed for any target, is given on Figure 5A: (1) a transition path was determined 
that consisted of a series of ordered intermediate conformations between the protein inactive and active 
forms; (2) a putative binding site was then identified by analyzing the evolution of cavities along the 
path; (3) virtual screening was performed on the chosen pocket and about 20 hits were selected and 
tested by in vitro experiments; (4) this led to the discovery of a new family of inhibitors, sharing a 
common thiophen ureioacids scaffold. This overall strategy is described in more details in the 
following sections. 
Figure 5. Use of EF conformational transition to search for allosteric inhibitors.  
(A) Workflow of the inhibitor identification; (B) Rational structural basis for an inhibition 
established by mean of an allosteric interaction. EF and CaM are drawn in cartoon and the 
TUA compound in licorice. CaM is colored in lime green, and the SABC pocket in yellow. 
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4.3. Identification of the Potential Binding Site 
EF undergoes a very large and complex structural transition whilst it is activated upon binding of 
CaM. In the presence of CaM, the helical domain is subjected to a translation of 15 Å with a rotation 
of 30°, and several loops are reorganized to form the catalytically competent ATP site. These 
functional motions would have been difficult if not impossible to isolate/observe experimentally and 
advanced molecular modeling techniques were used to build plausible intermediate states. Hence, the 
conformational transition was described in silico by the Path Optimization and Exploration, POE, 
approach [37] developed to extend the power of the conjugate-peak algorithm [67,68] by iteratively 
identifying transitional shortcuts and reassembling them in a continuous, low energy and short  
length path. 
Analysis of the cavities at the surface of the protein during this transition with in-house programs 
and ICM PocketFinder [69], covered, among others, already known cavities such as the catalytic site 
and cavities in the CB and Hel domains respectively [26,36]. 
It also pointed out a cavity displaying a strong shrinkage in the early stages of the activation 
transition path. This cavity was located mostly between the Switches A, B and C and was, thus, called 
the SABC pocket (Figure 5B). This pocket located on a side of the central region had never been 
reported as a site, which could be used to inhibit the toxin. 
As shown in section “Interplay between EF, calmodulin and calcium ions” the region connecting 
the domains CA and Hel appears particularly sensitive to the calcium level (Figure 3). These analyses 
also highlighted the importance of the central region of EF, namely Switches A, B and C, during the 
activation process. Consequently, the SABC pocket appears indeed as a favorable putative site to 
target in order to block EF activation by trapping the protein in an intermediate inactive conformation 
(Figure 5B). 
4.4. Identification of a New Family of Inhibitors 
Once the target site was identified, virtual compound libraries were screened on the initial step 
conformations of the activation path model to select binder candidates. Intermediate conformations 
(labeled on Figure 5B) were used to perform an additional virtual screening against candidate 
compounds that could be compatible with activation. From a short list of about 30 candidates, 18 were 
available from a library of chemical entities of the French CNRS (Chimiothèque Nationale). The 
identified inhibitors were issued from the chemical library of the CERMN (Centre d’Etudes et de 
Recherche sur le Médicament de Normandie), developed using a program of parallel synthesis [70,71] 
to produce a library of 1140 thiophen derivatives with potential pharmacological properties. Their 
inhibitory activity was characterized experimentally with an in vitro enzymatic assay based on the 
detection of inorganic pyrophosphate released upon ATP conversion into cAMP [37]. 
Among those 18 compounds, a series of six highly related compounds, sharing a common thiophen 
ureidoacid scaffold (TUA) with different substituting groups, displayed a significant inhibitory profile. 
One of the compounds, a dichloro-TUA exhibited a clear inhibition at 10 μM (80% inhibition) with an 
estimated IC50 of 2–3 μM. 
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Interestingly, those compounds exerted inhibition on the moderately homologous B. pertussis toxin, 
CyaA. Despite an overall low homology (25% identity in the catalytic domains), a pocket sharing 
significant identity and homology (40 and 80% respectively) with the SABC pocket of EF is present in 
the corresponding region of CyaA. Additionally, the compounds appeared more effective on EF before 
activation by CaM than after, showing obviously that the inhibition did not operate by competition on 
the active site. 
A systematic cavity analysis performed on representative conformations extracted from the MD 
trajectories of the EF-CaM complex, with 0, 2 or 4 Ca2+ bound on CaM showed [37] that larger SABC 
pocket volumes correlated with a collapse of the catalytic site, thus providing additional insight on 
possible allosteric influences at the atomic level. 
As a conclusion, ligand binding to SABC proved to impact activity through an allosteric effect. 
Allosteric inhibitor design is particularly interesting, as it provides opportunities to target a protein 
function by means of ligands that bind to sites distinct from the catalytic pocket. Noteworthy, it can 
also be used on non-enzymatic proteins. In the case of EF, since the catalytic site binds ATP, design of 
allosteric ligands avoids the conception of molecules that could interfere with ATP-binding cellular 
enzymes, and hence, problems of inhibitory promiscuity, side-effects, and general toxicity. 
Interestingly, a similar situation is encountered for kinases, a major class of pharmaceutical targets 
binding ATP, for which allosteric inhibitors provide opportunities to improve selectivity [72]. 
5. Conclusions 
Molecular modeling is an essential tool to build hypotheses on biomolecular function. This goes 
through the building of structural and mechanistic models of the involved biomolecular assemblies. It 
can be used to further analyze and understand how molecular systems work, for example through the 
design of strategies to probe protein activity. Along this line, molecular modeling can also be used to 
design ways to operate on biological and/or living materials, as, among many possibilities, through the 
design of an inhibitor. 
The large amount of available structural data on EF, owing to investment of Wei-Jen Tang’s team, 
has been essential for this approach. More specifically, access to both inactive and active forms of EF 
structure has been an inestimable piece of information. 
As EF undergoes a large conformational transition to produce the EF/CaM active complex, it 
appeared as an excellent model to elaborate such a strategy. This idea was supported by the molecular 
modeling analysis of the mutual influences and plasticity of the partners in the context of the 
conformational transition. 
One application of molecular modeling having practicable and valuable outcomes is to provide 
bases for the rational design of strategies to identify new types of inhibitors, especially allosteric ones, 
which are of major interest for the pharmaceutical industry. Various classes of targets can be cited, 
among which, GPCR and kinases [73,74]. 
Molecular modeling hypotheses and models allow for the elaboration of ambitious and innovative 
strategies, but the latter heavily relies on the quality of those models and hypotheses. Therefore, model 
validation is an essential step for such an approach. The biochemical validation of an inhibitor among 
rational design candidates appears as a rewarding validation of the long chain of hypotheses that was 
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built to elaborate the design strategy. Conversely, newly identified inhibitors can be used to further 
probe the activity mechanism. 
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